CLRB Stock Analysis: Buy, Sell, or Hold?
CLRB - Cellectar Biosciences INC NEW
$1.22
0.05 (4.27%)
▲
5d:
+7.02%
30d:
-41.2%
90d:
-49.59%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 12, 2026
18d
Get Alerted When CLRB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CLRB shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CLRB shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: CLRB is currently trading at $1.22, which is considered oversold relative to its 30-day fair value range of $1.28 to $2.15.
Technical Outlook: Technically, CLRB is in a strong downtrend. Immediate support is located at $1.12, while resistance sits at $1.60. The stock is showing strong short-term momentum, up 4.3% recently.
Market Sentiment: CLRB scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $11.50 (+842.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CLRB is in a strong downtrend. Immediate support is located at $1.12, while resistance sits at $1.60. The stock is showing strong short-term momentum, up 4.3% recently.
Market Sentiment: CLRB scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $11.50 (+842.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.28 -
$2.15
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
100.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.3%)
- BULLISH: Trading 842.6% below Wall St target ($11.50)
- WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.28 -
$2.15
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.12
Resistance Level
$1.60
Current Trend
Strong Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.64
Wall Street Target
$11.50
(+842.6%)
Share & Embed Analysis
Last updated: October 23, 2026 10:49 PM ET
Data refreshes hourly during market hours. Next update: 11:49 PM
Data refreshes hourly during market hours. Next update: 11:49 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLRB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
STRONG BUY
25 analysts |
$84 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
16 analysts |
$106 | 50 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
|
TSHA
Taysha Gene Therapies Inc |
STRONG BUY
13 analysts |
$13 | 58 HOLD |
